Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025EMJ HematologyOpen Access

Recent Developments in Chronic Lymphocytic Leukaemia Research: Interview with an Expert

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBart L. Scott

Discussion

Loading...

Member takes

Overview

Expert interview discusses advances in chronic lymphocytic leukaemia treatments and highlights targeted therapies.

Key Points

  • Management of chronic lymphocytic leukaemia remains challenging despite effective targeted therapies.
  • Key therapies include bruton tyrosine kinase inhibitors like acalabrutinib and venetoclax.
  • Emerging therapies like pirtobrutinib and epcoritamab provide new options for patients with CLL.
  • Future developments may focus on individualized therapy tailored to patients' specific needs.

Cite This Study

Bart L. Scott (2025) studied this question.

synapsesocial.com/papers/68c1a40954b1d3bfb60de740https://doi.org/10.33590/emjhematol/iqcc8658
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?2025
  2. 2The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs2025
  3. 3Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia2024 · 2 citations
  4. 4Updates in the management of newly diagnosed chronic lymphocytic leukemia2025 · 1 citations
  5. 5An international view on the current approaches to frontline chronic lymphocytic leukemia therapy2025